Zusammenfassung
Das Ovarialkarzinom ist der gynäkologische Tumor mit der höchsten Mortalität. Der interdisziplinären chirurgischen Therapie fällt ein hoher Stellenwert zu. In letzter Zeit hat es zahlreiche neue Erkenntnisse über den Stellenwert und Umfang der operativen Therapie dieser Erkrankung gegeben. Die Umsetzung dieser in nationalen und internationalen Standards und Leitlinien implementierten neuen Entwicklungen in den klinischen Alltag ist zur Verbesserung der Situation der Betroffenen dringend erforderlich.
Abstract
Epithelial ovarian cancer is the gynecological tumor with the highest mortality rate. Numerous findings have recently emerged about the value and extent of surgical therapy of this disease. Already applied to national and international standards and guidelines, these new developments must become part of clinical practice if patients are to benefit.
Literatur
Aletti GD, Dowdy SC, Gostout BS et al. (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107: 77–85
Armstrong DK, Bundy B, Wenzel L et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43
Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259
Cliby W, Dowdy S, Feitoza SS et al. (2004) Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol 94: 655–660
du Bois A, Rochon J, Lamparter C, Pfisterer J (2005) Ovarialkarzinom – Versorgungsstruktur und -qualität in Deutschland 2001–2004. Frauenarzt 46: 560–567
Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al. (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103: 1083–1090
Eisenkop SM, Spirtos NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82: 489–497
Elit L, Chartier C, Oza A et al. (2006) Outcomes for systemic therapy in women with ovarian cancer. Gynecol Oncol 103: 554–558
Estes JM, Leath CA 3rd, Straughn JM Jr et al. (2006) Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg 203: 527–532
Fanning J, Hilgers RD (1995) Loop electrosurgical excision procedure for intensified cytoreduction of ovarian cancer. Gynecol Oncol 57: 188–190
Hoffman MS, Griffin D, Tebes S et al. (2005) Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol 193: 582–586
Kommission Ovar der AGO (2007) Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. Zuckschwerdt, Germering
Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2: 21
Rose PG (1992) The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 166: 843–846
Rose PG, Nerenstone S, Brady MF et al. Gynecologic Oncology Group (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–2497
Tebes SJ, Cardosi R, Hoffman MS (2006) Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obstet Gynecol 195: 585–589
Burg ME van der, Lent M van, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332: 629–634
Walker JL, Armstrong DK, Huang HQ et al. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100: 27–32
Wenzel LB, Huang HQ, Armstrong DK et al. (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 437–443
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Anhang
Anhang
Rights and permissions
About this article
Cite this article
Pfisterer, J., Harter, P., Hilpert, F. et al. Peritoneal metastasiertes Ovarialkarzinom. Chirurg 78, 1111–1116 (2007). https://doi.org/10.1007/s00104-007-1431-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-007-1431-4